
Novartis and Eisai have abandoned their co-promotion agreement for three of Novartis’ chronic obstructive pulmonary disease treatments. The move follows …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

